Adefovir dipivoxil
- Generic Name
- Adefovir dipivoxil
- Brand Names
- Hepsera
- Drug Type
- Small Molecule
- Chemical Formula
- C20H32N5O8P
- CAS Number
- 142340-99-6
- Unique Ingredient Identifier
- U6Q8Z01514
- Background
Adefovir dipivoxil, previously called bis-POM PMEA, with trade names Preveon and Hepsera, is an orally-administered acyclic nucleotide analog reverse transcriptase inhibitor (ntRTI) used for treatment of hepatitis B. It is ineffective against HIV-1. Adefovir dipivoxil is the diester prodrug of adefovir.
- Indication
Indicated for the treatment of chronic hepatitis B in adult patients with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease; this is based on histological, virological, biochemical, and serological responses in adult patients with HBeAg+ and HBeAg- chroni...
- Associated Conditions
- Chronic Hepatitis B Infection
- Associated Therapies
- -
Observational Study of the Durability of Seroconversion Chronic HBV Patients Who Seroconverted in a Previous Gilead-Sponsored Study of ADV.
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2014-01-07
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 107
- Registration Number
- NCT00158717
Telbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive, Compensated Chronic Hepatitis B
- Conditions
- First Posted Date
- 2005-06-22
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- Novartis
- Registration Number
- NCT00115245
Treatment of Hepatitis in Patients Who Are Triple-Infected With HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV)
- Conditions
An Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients With Lamivudine-Resistant Chronic Hepatitis B With Limited Treatment Options
- Conditions
- First Posted Date
- 2002-08-01
- Last Posted Date
- 2014-01-07
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT00042393
A Comparison of Adefovir and Tenofovir for the Treatment of Lamivudine-Resistant Hepatitis B Virus in People With HIV
- Conditions
- First Posted Date
- 2002-04-09
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 90
- Registration Number
- NCT00033163
- Locations
- 🇺🇸
Northwestern University CRS, Chicago, Illinois, United States
🇺🇸Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States
🇺🇸Univ. of Cincinnati CRS, Cincinnati, Ohio, United States
Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 440
- Registration Number
- NCT00000885
- Locations
- 🇺🇸
Johns Hopkins Hosp, Baltimore, Maryland, United States
🇺🇸Division of Inf Diseases/ Indiana Univ Hosp, Indianapolis, Indiana, United States
🇺🇸Boston Med Ctr, Boston, Massachusetts, United States
Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 25
- Registration Number
- NCT00002234
- Locations
- 🇺🇸
Pacific Oaks Med Group, Beverly Hills, California, United States
🇺🇸Univ of Colorado / Health Science Ctr, Denver, Colorado, United States
🇺🇸AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 120
- Registration Number
- NCT00002184
- Locations
- 🇺🇸
Krauss Med Partners / Dept of Research and Development, Los Angeles, California, United States
🇺🇸UCLA Care Ctr, Los Angeles, California, United States
🇵🇷Hosp Regional de Ponce - Area Vieja, Ponce, Puerto Rico
Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor Treatment
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 25
- Registration Number
- NCT00002419
- Locations
- 🇺🇸
Brown Univ School of Medicine, Providence, Rhode Island, United States
🇺🇸AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
🇺🇸Pacific Oaks Med Group, Beverly Hills, California, United States
The Safety and Effectiveness of Bis-POM PMEA in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 36
- Registration Number
- NCT00002346
- Locations
- 🇺🇸
Johns Hopkins Univ, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.